The trend of musicians getting into the marijuana business continues. Wu-Tang Clan rapper Ghostface Killah is lending his star power to a new line of concentrated hash oil cartridges called “Woo Goo.” In a bizarre new infomercial, Ghostface introduces the product (“this shit here’s organic!”) with the help of a blonde pitchwoman, who (of course) ends […]

by

COSTA MESA, CA — (Marketwired) — 03/29/16 — Sipp Industries, Inc. (OTC: SIPC), a diversified conglomerate corporation specializing in technology, manufacturing and distribution of commercial and consumer products announces a distribution agreement with Evolved Ayurvedic Discoveries, Inc (EAD Labs). Operating through its wholly owned subsidiary, Major Hemp, the Company will partner with EAD Labs to […]

by

PORTLAND, OR–(Marketwired – April 15, 2016) – Pharmer’s Market, Oregon’s leading wholesale distributor of cannabis infused OMMP-compliant products, today announced it’s expanding its services to Portland, as well as the rest of Northern Oregon. Pharmer’s Market offers specialty, wellness, and ancillary products, including lab-tested premium CO2 cannabis oil cartridges, dabs, edibles,… read more at: http://news.sys-con.com/node/3770270

by

The United Kingdom’s GW Pharmaceuticals may be on the eve of a medical first in the United States: Obtaining approval from the Food and Drug Administration (FDA) for a wholly cannabis-derived drug, Epidiolex.   On Monday, March 14, the company announced that Epidiolex had successfully passed the latest test of its claimed ability to treat […]

by

So much for making it three days in a row! After posting decent gains both Friday and Monday – especially for Biotech Forum favorites Dynavax Technologies (NASDAQ:DVAX) and Relypsa (NASDAQ:RLYP)– the biotech sector gave it all back and more on Tuesday, dropping almost four percent. Click to enlarge The disaster that one-time darling Valeant Pharmaceuticals […]

by

MEAUX, FRANCE – AUGUST 25: A field of legal cannabis plants selected for their low content of THC grows on August 25, 2014 near Meaux, France. (Photo : Sean Gallup/Getty Images) On Monday, March 14, GW Pharma announced that its cannabis drug, Epidiolex, has proved successful in a late-stage trial. The drug has reduced substantially the number […]

by

PUNE, India, March 28, 2016 /PRNewswire/ — New market research titled “Peripheral Neuropathy (Sensory Neuropathy) – Pipeline Review, H2 2015” provides an overview of the Peripheral Neuropathy’s therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens RD pipelines by identifying new targets and […]

by

Photo Credit: Blablo101/Shutterstock.com What are the best plants for extracting and making high quality CBD-rich oil? Marijuana, industrial hemp, both? Let’s cut through the legal mumbo jumbo, the obfuscating nomenclature, and the marketing hype and let’s look at what’s really out there for sourcing CBD-rich oil. In the cannabis world there are two types of […]

by

Positive results have been reported from a phase 3 study of the investigational medication cannabidiol (Epidiolex, GW Pharmaceuticals) in patients with Dravet syndrome, a rare and debilitating type of infantile-onset epilepsy for which no treatments are currently available in the U.S. Cannabidiol achieved the trial’s primary endpoint of a significant reduction in convulsive seizures assessed […]

by

Zynerba Pharmaceuticals (NASDAQ:ZYNE), a developer of transdermal synthetic cannabinoid treatments, published data that demonstrates the acidic pH conditions provided by simulated gastric fluid converts cannabidiol (CBD) into psychoactive components tetrahydrocannabinol (THC) and cannabinoids. In a paper titled Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid, which was published online in Cannabis […]

by

London, (GLOBE NEWSWIRE) – GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that it has commenced a Phase 3 clinical trial of Epidiolex® (cannabidiol or CBD) as an adjunctive therapy for the treatment of seizures […]

by